Systemic Fibrinolytic Therapy Versus Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute İntermediate-High Risk Pulmonary Embolism
Section snippets
Disclosures
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
References (6)
- et al.
Moderate pulmonary embolism treated with thrombolysis (from the ‘MOPETT’ trial)
Am J Cardiol
(2013) - et al.
Hemodynamic effects of ultrasound-assisted, catheter-directed, very low-dose, short-time duration thrombolysis in acute intermediate-high risk pulmonary embolism (from the EKOS-PL Study)
Am J Cardiol
(2020) - et al.
Clinical safety and efficacy of thrombolytic therapy with low-dose prolonged infusion of tissue type plasminogen activator in patients with intermediate-high risk pulmonary embolism
Blood Coagul Fibrinolysis
(2020)
There are more references available in the full text version of this article.
Cited by (0)
Funding: The author(s) received no financial support for the research, authorship, and/or publication of this article.
© 2020 Elsevier Inc. All rights reserved.